Evidence map›Paper›PMID 42014520›Full record

ReviewCellular and molecular life sciences : CMLS2026

Game of clones: decipher lineage plasticity in hormone-driven cancers.

Amanda Leonita, Siyuan Cheng, Joshua Warrick, Isaac Yi Kim, Su Deng, Ping Mu

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda LeonitaDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511, USA.
Siyuan ChengDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511, USA.
Joshua WarrickDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06511, USA.
Isaac Yi KimDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511, USA.
Su DengDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511, USA.
Ping MuDepartment of Urology, Yale University School of Medicine, New Haven, CT, 06511, USA. ping.mu@yale.edu.ORCID http://orcid.org/0000-0003-0955-0896

Funding

Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy ResistanceR37CA258730 · NCI · YALE UNIVERSITY · PI Ping Mu · 2021 to 2026
$2.7M
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor DegradationR01CA292949 · NCI · YALE UNIVERSITY · PI Ping Mu · 2024 to 2026
$2.1M
Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate CancerR01CA288820 · NCI · YALE UNIVERSITY · PI Ping Mu · 2024 to 2026
$820k
NCI NIH HHS R01 CA288820NCI NIH HHS R01CA288820NCI NIH HHS R01CA292949NCI NIH HHS R37CA258730Prostate Cancer Foundation (US) 17YOUN12Prostate Cancer Foundation (US) 25CHAL05Yale Cancer Center CCSG Pilot Grant P30CA016359
6 · The paper itself

Abstract

Hormone-dependent cancers such as prostate, breast, and endometrial carcinomas rely on nuclear hormone receptors to sustain lineage identity and growth. Therapies targeting androgen, estrogen, or progesterone signaling are initially effective but ultimately impose selective pressures that drive resistance through lineage plasticity, the ability of tumor cells to abandon their native identity and adopt alternative cellular fates. While the biological consequences of lineage plasticity are increasingly recognized, a major challenge lies in defining the regulatory programs that govern these cell fate transitions and determine their stability, directionality, and therapeutic vulnerability. In this review, we focus on the regulatory modules that underlie lineage plasticity in hormone-driven cancers. We highlight how integrative multi-omics approaches spanning genomic, transcriptomic, epigenomic, proteomic, and chromatin-level layers have enabled the identification of transcriptional and epigenetic programs that destabilize lineage fidelity. We discuss how single-cell and spatial technologies have revealed intermediate states, rare subpopulations, and microenvironmental influences that shape plasticity trajectories. Finally, we emphasize the role of artificial intelligence and machine learning as integrative tools to reconstruct gene regulatory circuits, infer fate transitions, and connect molecular programs to phenotypic outcomes. By synthesizing these biological insights across experimental and computational modalities, we propose a conceptual framework for understanding lineage plasticity in hormone-driven cancers, with emphasis on prostate and breast malignancies. This integrated perspective highlights how regulatory programs governing cell identity can be revealed, perturbed, and potentially constrained, offering opportunities to identify biomarkers, expose therapeutic vulnerabilities, and ultimately translate mechanistic understanding into strategies that limit resistance.

Indexed as

Cell LineageHormonesNeoplasmsNeoplasms, Hormone-DependentAnimalsCell PlasticityGene Expression Regulation, NeoplasticHumansHormonesArtificial intelligenceHormone-dependent cancersLineage plasticityMulti-omics approachesRegulatory modules

Identifiers

PMID42014520
PMCPMC13237331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.